We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+0.81%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$328M
AUM Growth
-$55.1M
Cap. Flow
-$44.7M
Cap. Flow %
-13.62%
Top 10 Hldgs %
42.21%
Holding
136
New
34
Increased
27
Reduced
16
Closed
41

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$14.8M
2
SLNO
Soleno Therapeutics
SLNO
+$14.3M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.24M
4
TGTX icon
TG Therapeutics
TGTX
+$6.09M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$4.61M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.5M
2
ARGX icon
argenx
ARGX
+$3.66M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.54M
4
LLY icon
Eli Lilly
LLY
+$3.49M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$2.65M

Sector Composition

Rank Sector Weight
1 Healthcare 49.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLNO
1
DELISTED
Soleno Therapeutics
SLNO
$23.8M 7.25%
284,152
+191,150
+206% +$14.3M
AMGN icon
2
PUT
Amgen
AMGN
$208B
$17.3M 5.28%
62,100
+10,000
+19% +$2.83M
LLY icon
3
PUT
Eli Lilly
LLY
$1.02T
$16.1M 4.92%
20,700
– –
AMGN icon
4
Amgen
AMGN
$208B
$14.5M 4.43%
+52,100
New +$14.8M
TGTX icon
5
TG Therapeutics
TGTX
$7.96B
$13.4M 4.07%
371,448
+163,565
+79% +$6.09M
NBIX icon
6
Neurocrine Biosciences
NBIX
$16.8B
$11.8M 3.6%
94,042
+31,795
+51% +$3.65M
LLY icon
7
Eli Lilly
LLY
$1.02T
$11.5M 3.52%
14,816
-4,486
-23% -$3.49M
JAZZ icon
8
Jazz Pharmaceuticals
JAZZ
$15.9B
$11.1M 3.38%
104,473
+17,284
+20% +$1.88M
BMRN icon
9
BioMarin Pharmaceuticals
BMRN
$11.6B
$10.6M 3.23%
192,877
+140,000
+265% +$8.24M
XBI icon
10
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$8.29M 2.53%
+100,000
New +$7.98M
RARE icon
11
CALL
Ultragenyx Pharmaceutical
RARE
$2.45B
$7.89M 2.4%
217,000
+100,000
+85% +$3.61M
LLY icon
12
CALL
Eli Lilly
LLY
$1.02T
$7.8M 2.38%
10,000
– –
RVMD icon
13
CALL
Revolution Medicines
RVMD
$39.9B
$7.36M 2.24%
+200,000
New +$7.68M
CORT icon
14
PUT
Corcept Therapeutics
CORT
$12.4B
$7.35M 2.24%
100,200
-50,000
-33% -$3.63M
NVO
15
CALL
Novo Nordisk
NVO
$208B
$6.9M 2.1%
100,000
-8,700
-8% -$592K
APGE icon
16
CALL
Apogee Therapeutics
APGE
$10.1B
$6.79M 2.07%
156,300
+30,000
+24% +$1.14M
PCVX icon
17
Vaxcyte
PCVX
$7.81B
$6.45M 1.96%
198,285
+105,900
+115% +$3.47M
BBIO icon
18
CALL
BridgeBio Pharma
BBIO
$15.7B
$5.67M 1.73%
131,400
– –
CRSP icon
19
CALL
CRISPR Therapeutics
CRSP
$4.73B
$5.45M 1.66%
112,000
– –
JAZZ icon
20
CALL
Jazz Pharmaceuticals
JAZZ
$15.9B
$5.31M 1.62%
50,000
-20,800
-29% -$2.26M
VKTX icon
21
Viking Therapeutics
VKTX
$3.7B
$5.23M 1.59%
197,468
+93,347
+90% +$2.46M
SPRY icon
22
CALL
ARS Pharmaceuticals
SPRY
$509M
$4.9M 1.49%
+280,700
New +$4.05M
ALT icon
23
CALL
Altimmune
ALT
$552M
$4.89M 1.49%
1,262,900
+844,100
+202% +$4.57M
PFE icon
24
CALL
Pfizer
PFE
$143B
$4.85M 1.48%
200,000
-700,000
-78% -$16.3M
RARE icon
25
PUT
Ultragenyx Pharmaceutical
RARE
$2.45B
$4.48M 1.37%
123,300
– –
1
2 3 4 5

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Diadema Partners held 136 positions worth $328M, down 14% from $383M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Diadema Partners withdrew a net $44.7M in Q2 2025, closing 41 positions and reducing 16 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $3.54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, up from 33% a quarter earlier.

Against the trend, Diadema Partners opened a new position in Amgen worth $14.5M.

  • Diadema Partners's largest Q2 2025 buy was Amgen: 52,100 shares worth $14.5M.
  • Diadema Partners added most to Soleno Therapeutics in Q2 2025, an estimated $14.3M increase.
  • Diadema Partners's biggest Q2 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $13.5M.
  • Diadema Partners fully exited Alnylam Pharmaceuticals in Q2 2025, selling an estimated $3.54M.
  • Diadema Partners's ten largest holdings make up 42% of its $328M portfolio in Q2 2025.
  • Diadema Partners opened 34 new positions and closed 41 in Q2 2025.
  • Diadema Partners's portfolio value fell 14% quarter-over-quarter to $328M.

Based on Diadema Partners's 13F filing for Q2 2025, filed 14 Aug 2025.